Scientists have long known about such animal kinship attachments, some known as “imprinting,” but the mechanisms underlying them have been hidden in a black box at the cellular and molecular levels. Now, biologists at the University of California San Diego have unlocked key elements of these mysteries, with implications for understanding social attraction and aversion in a range of animals and humans.
Laurel Riek, associate professor of Computer Science and Engineering at the University of California San Diego, will lead a three-year National Science Foundation (NSF) project on new methods for coordinating teams of robots and people in complex, uncertain environments.
In mouse experiments, researchers at University of California San Diego School of Medicine have discovered that drugs that activate the cells’ proteasome, or recycling center, tip the balance in favor of memory CD8+ T cells. This approach could be used to improve how well vaccines and immunotherapies work and how long they last.
More than one-and-a-half years after implantation, researchers at University of California San Diego School of Medicine and the San Diego Veterans Administration Medical Center report that human neural stem cells (NSCs) grafted into spinal cord injuries in laboratory rats displayed continued growth and maturity, with functional recovery beginning one year after grafting.
On Aug. 29, UC San Diego archaeologist Tom Levy leads an expedition for the first-ever desert land-and-sea integrated cyber-archaeology project to be carried out in Israel, and the expedition will be flying The Explorers Club flag (as Levy did in 2011 with an expedition to southern Jordan).
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) today unanimously approved an $18.29 million grant to University of California San Diego School of Medicine researchers to fund a phase Ib/IIa clinical trial of a novel combination drug therapy for B-cell cancers.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
